News & Events
Treatment Success in Reducing Recurrent Clostridioides difficile Infection with Investigational Live Biotherapeutic RBX2660 is Associated with Microbiota Restoration: Consistent Evidence from a Phase 3 Clinical Trial (opens in a new tab)
Ken Blount1, Dana Walsh1, Carlos Gonzalez2, Bill Shannon2 1Rebiotix, Inc., a Ferring Company, Roseville, MN, USA; 2 BioRankings LLC St. Louis, MO, USA Background Several investigational microbiota-based live biotherapeutics are in clinical development for reducing recurrence of Clostridioides difficile infection (rCDI)…
Safety of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data From Five Prospective Clinical Studies (opens in a new tab)
Tricia Braun PharmD, Beth Guthmueller, Adam Harvey PhD 1Rebiotix, Inc. Roseville, MN, USA; 2BioRankings LLC St. Louis, MO, USA Background Microbiota-based treatments have shown promise to reduce recurrence, morbidity, and mortality for recurrent Clostridioides difficile infections (rCDI), but consistent and reliable sa…
Antimicrobial Resistance Genes were Reduced Following Administration of Investigational Live Biotherapeutic RBX2660 to Individuals with Recurrent Clostridioides Infection (opens in a new tab)
Heidi Hau, PhD1, Dana Walsh PhD1, Carlos Gonzalez MS2, Bill Shannon PhD MBA2, Ken Blount1 1Rebiotix Inc, a Ferring company, Roseville, MN, USA; 2BioRankings, St. Louis, MO, USA Background Microbiota-based treatments are increasingly evaluated as a strategy to reduce recurrence of Clostridioides difficile infection (rCD…
Rapid Restoration of Bile Acid Compositions After Treatment with RBX2660 for Recurrent Clostridioides difficile Infection—Results from the PUNCH CD3 Phase 3 Trial (opens in a new tab)
Sahil Khanna MBBS, MS, Ken Blount PhD, Romeo Papazyan1, Bryan C. Fuchs1, Ken Blount2, Carlos Gonzalez3, Bill Shannon3 1Ferring Research Institute, San Diego, CA, USA; 2Rebiotix, Inc., a Ferring Company, Roseville, MN, USA; 3BioRankings LLC St. Louis, MO, USA Background Microbiota-based treatments are increasingly evalu…
Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021 (opens in a new tab)
– In ECOSPOR III, investigational microbiome therapy SER-109 was associated with greater reduction of antimicrobial resistance genes in patients with recurrent CDI compared to placebo – CAMBRIDGE, Mass. –(BUSINESS WIRE)–Oct. 2, 2021– Seres Therapeutics, Inc.…
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties (opens in a new tab)
Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as a whole, comprising the largest, most robust program ever conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection (rCDI) Only gut microbiom…
Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021 (opens in a new tab)
Analysis of data from five RBX2660 prospective studies is one of only four abstracts to receive the coveted IDWeek 2021 Program Committee Choice award for outstanding scientific research. Ferring and Rebiotix will present new data showing an association between clinical outcomes and restoration of the microbiome Resear…
Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection (opens in a new tab)
– Data presented highlights significant impact of SER-109 on health-related quality of life (HRQoL) and reduction of recurrence regardless of risk factors – – Preclinical assessments support the ability of SER-155 to decolonize antibiotic-resistant pathogens, potentially reducing the risk of…
Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection (opens in a new tab)
– Seres expects both the completed Phase 3 study results and the pending open-label study database to finalize a Biologics License Application (BLA) filing in mid-2022 – – Potential to be first-ever FDA-approved microbiome therapy – CAMBRIDGE, Mass. –(BUSINESS WIRE)–Sep.…
Developing Microbiome Rehabilitation Biomarkers for Clostridium difficile Infections: Evaluation and Plan of a Prototype MICROBIOME HEALTH INDEX™ (MHI™) (opens in a new tab)
Ken Blount PhD, Courtney Jones BS, Sharina Carter PhD, Elena Deych MS, Bill Shannon PhD MBA Background Because Clostridium difficile infections (CDI) are strongly associated with dysbiosis, or disruption of a healthy microbiome, there are several clinical development programs in progress to develop FDA-approved microbi…
Experienced professional to head US business development (opens in a new tab)
Dr Jean-Philippe Laine joins as US Director of Business Development to drive forward global research and discovery partnerships. The post Experienced professional to head US business development appeared first on Microba Life Sciences.…
Anatara’s IBS-D clinical trial to leverage Microba’s precision microbiome analysis (opens in a new tab)
Microba will work with Anatara to complete microbiome analysis for a much-needed therapeutic treatment for sufferers of IBS-D. The post Anatara’s IBS-D clinical trial to leverage Microba’s precision microbiome analysis appeared first on Microba Life Sciences.…
Microbiome research: the new frontier (opens in a new tab)
Experts will present opportunities for harnessing the microbiome for innovative products, therapies and diagnostics to a global audience. The post Microbiome research: the new frontier appeared first on Microba Life Sciences.…
Seres Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Aug. 5, 2021– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff , President and Chief Executive Officer of Seres Therapeutics , will participate in a discussion at the Canaccord Genuity 41st…
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates (opens in a new tab)
– SER-109 open-label study in patients with recurrent C. difficile infection on track to achieve enrollment target in late Q3 2021 – – SER-109 co-commercialization agreement with Nestlé Health Science provides $310 million in upfront and contingent approval milestones, additional $225 million in…
Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jul. 29, 2021– Seres Therapeutics, Inc. , (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2021 at 8:30 a.m.…
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jul. 22, 2021– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss topline results from the Phase 2b ECO-RESET…
Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis (opens in a new tab)
—Primary endpoint of clinical remission compared to placebo was not achieved— —Both dosing regimens of SER-287 were generally well tolerated— —Open label and maintenance portions of the SER-287 study will be closed— — Microbiome endpoints and analyses expected in the second half of 2021— —Company…
Vedanta Biosciences Completes $68 Million Series D Financing (opens in a new tab)
Proceeds expected to be used primarily to support a Phase 3 trial of lead candidate VE303 in Clostridioides difficile infection (CDI) and a Phase 2 trial of VE202 in inflammatory bowel disease (IBD) Topline data from Phase 2 trial of VE303 in CDI are anticipated in Q3 2021 Plans to initiate Phase 2 trial of VE202 for t…
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement (opens in a new tab)
Companies Agree to Jointly Commercialize SER-109 Investigational Microbiome Therapeutic to Treat Recurrent C. difficile Infection, Leading the Way for Entirely New Treatment Modality Deal calls for more than $500 million in upfront and contingent milestone payments Seres Therapeutics to conduct a…